Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CHL1 antisense RNA 1 (non-protein coding) (CHL1-AS1)
- Target
- CHL1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-protein coding transcript, Regulatory RNA
01
Overview
CHL1 antisense RNA 1 (CHL1-AS1) is a long non-coding RNA transcribed antisense to the CHL1 gene, located on human chromosome 3. CHL1-AS1 does not code for a protein; rather, it regulates biological functions by modulating CHL1 expression and acting as a molecular sponge for specific microRNAs, notably miR-6076. Its expression pattern is closely mirrored with that of CHL1 in several diseases, including endometriosis and various cancers, where it contributes to pathological cell proliferation and migration. CHL1-AS1 functions as a regulatory RNA involved in the development and progression of tumors and endometrial pathologies and has emerged as a potential biomarker and therapeutic target in these conditions.
- Other names
- CHL1-AS1CHL1 antisense RNA 1CHL1-AS1 (non-protein coding)
02
Mechanism of action
Acts through microRNA sponging (e.g., miR-6076), thereby regulating the expression of CHL1 and influencing cell proliferation and migration. siRNA-mediated knockdown inhibits proliferation and migration in experimental models (not a clinical drug but a mechanism used in functional studies).
03
Biological functions
Regulation of cell proliferationRegulation of cell migrationModulation of gene expression (cis-regulation of CHL1, a neural cell adhesion molecule)Competing endogenous RNA (ceRNA) activity (sponging microRNAs such as miR-6076)Involved in endometrial tissue remodeling
04
Disease associations
Cancer (notably endometrial cancer, glioma, and ovarian endometriosis)Endometriosis
05
Safety considerations
No specific safety concerns reported for targeting CHL1-AS1, but general risks associated with RNA-based therapies (off-target effects, immune activation, delivery challenges) may apply (inferred from the field; not explicitly given in results).
06
Biomarkers
Elevated levels of CHL1-AS1 serve as biomarkers for endometrial cancer and ovarian endometriosisExpression correlated with disease progression in several cancers (via parallel expression with CHL1)
Beyond the preview
Go deeper on CHL1 antisense RNA 1 (non-protein coding) (CHL1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHL1 antisense RNA 1 (non-protein coding) (CHL1-AS1).